Kidney damage associated with anti-phospholipid syndrome

I.Yu. Golovach, Ye.D. Yehudina, D.G. Rekalov


Antiphospholipid syndrome (APS) is a common autoimmune disease caused by pathogenic antiphospholipid antibodies, leading to recurrent thrombosis and/or obstetric complications. It is important for nephrologists to know that the combination of the antiphospholipid antibody presence associating with various clinical manifestations of kidney damage caused by thrombosis of large renal vessels, renal artery stenosis and intrarenal lesions leads to the antiphospholipid nephropathy development. This condition is associated with acute thrombotic microangiopathy of varying severity, proliferative and fibrous lesions of the intrarenal vessels and ischemic changes in the renal parenchyma. The course of the disease can range from slow progressive nephropathy to life-threatening acute renal failure. The development of secondary antiphospholipid nephropathy associated with antiphospholipid antibodies in the context of systemic lupus erythematosus is the most studied and widely known. In contrast, the clinical significance of isolated antiphospholipid nephropathy remains uncertain and poorly understood. The evidence base for drugs aimed at treating renal complications of APS is limited. However, the recent recognition of heterogeneous molecular mechanisms underlying the progression of intrarenal vascular lesions in APS has opened up promising ways for monitoring patients and target therapeutic interventions.


antiphospholipid syndrome; antiphospholipid antibodies; nephropathy; thrombotic microangiopathy; renal thrombosis


Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.x.

Turrent-Carriles А, Herrera-Félix JB, Mary-Amigo С. Renal Involvement in Antiphospholipid Syndrome. Front Immunol. 2018 May 17;9:1008. doi: 10.3389/fimmu.2018.01008.

Merashli M, Noureldine MH, Uthman I, Khamashta M. Antiphospholipid syndrome: an update. Eur J Clin Invest. 2015 Jun;45(6):653-62. doi: 10.1111/eci.12449.

Sinico RA, Cavazzana I, Nuzzo M, et al. Renal involvement in primary antiphospholipid syndrome: retrospective analysis of 160 patients. Clin J Am Soc Nephrol. 2010 Jul;5(7):1211-7. doi: 10.2215/CJN.00460110.

Parodis I, Arnaud L, Gerhardsson J, et al. Antiphospholipid Antibodies in Lupus Nephritis. PLoS One. 2016 Jun 23;11(6):e0158076. doi: 10.1371/journal.pone.0158076.

Silvariño R, Sant F, Espinosa G, et al. Nephropathy associated with antiphospholipid antibodies in patients with systemic lupus erythematosus. Lupus. 2011 Jun;20(7):721-9. doi: 10.1177/0961203310397410.

Zheng H, Chen Y, Ao W, et al. Antiphospholipid antibody profiles in lupus nephritis with glomerular microthrombosis: a prospective study of 124 cases. Arthritis Res Ther. 2009;11(3):R93. doi: 10.1186/ar2736.

Tektonidou MG, Sotsiou F, Moutsopoulos HM. Antiphospholipid syndrome (APS) nephropathy in catastrophic, primary, and systemic lupus erythematosus-related APS. J Rheumatol. 2008 Oct;35(10):1983-8.

Gao R, Yu W, Wen Y, Li H. Beta2-glycoprotein I expression in lupus nephritis patients with antiphospholipid-associated nephropathy. J Rheumatol. 2016 Nov;43(11):2026-2032. doi: 10.3899/jrheum.151395.

Romanidou G, Konstantinidis TG, Koutsogiannis O, et al. Study of Antiphospholipid Antibodies in Patients with Arterial Hypertension. Med Sci (Basel). 2018 Nov 13;6(4). pii: E102. doi: 10.3390/medsci6040102.

Smyth A, Oliveira GH, Lahr BD, Bailey KR, Norby SM, Garovic VD. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol. 2010 Nov;5(11):2060-8. doi: 10.2215/CJN.00240110.

Gigante A1, Gasperini ML, Cianci R, et al. Antiphospholipid Antibodies and Renal Involvement. Am J Nephrol. 2009;30(5):405-12. doi: 10.1159/000235941.

Nasri H. Antiphospholipid syndrome-associated ephropathy: Current concepts. J Renal Inj Prev. 2013 Mar 1;2(1):1-2. doi: 10.12861/jrip.2013.01.

Barbour TD, Crosthwaite A, Chow K, et al. Antiphospholipid syndrome in renal transplantation. Nephrology (Carlton). 2014 Apr;19(4):177-85. doi: 10.1111/nep.12217.

Choi JY, Jung JH, Shin S, Kim YH, Han DJ. Living donor renal transplantation in patients with antiphospholipid syndrome. Medicine (Baltimore). 2016 Nov;95(46):e5419. doi: 10.1097/MD.0000000000005419.

Morales JM, Serrano M, Martinez-Flores JA, et al. The presence of pretransplant antiphospholipid antibodies IgA anti-beta-2-glycoprotein I as a predictor of graft thrombosis after renal transplantation. Transplantation. 2017 Mar;101(3):597-607. doi: 10.1097/TP.0000000000001199.

Meroni PL, Chighizola CB, Rovelli F, Gerosa M. Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Res Ther. 2014;16(2):209. doi: 10.1186/ar4549.

Arachchillage DR, Efthymiou M, Mackie IJ, Lawrie AS, Machin SJ, Cohen H. Antiprotein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome. J Thromb Haemost. 2014 Nov;12(11):1801-9. doi: 10.1111/jth.12722.

Brandt KJ, Kruithof EK, de Moerloose P. Receptors involved in cell activation by antiphospholipid antibodies. Thromb Res. 2013 Oct;132(4):408-13. doi: 10.1016/j.thromres.2013.08.015.

Willis R, Pierangeli SS. Pathophysiology of the antiphospholipid antibody syndrome. Auto Immun Highlights. 2011 Mar 24;2(2):35-52. doi: 10.1007/s13317-011-0017-9.

Makarenko EV. Antiphospolipid syndrome. Health and ecology problems. 2017;4(54):4-11.

Yang YH, Chien D, Wu M, et al. Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin. J Immunol. 2009 Feb 1;182(3):1674-80. doi: 10.4049/jimmunol.182.3.1674.

Negrini S, Pappalardo F, Murdaca G, Indiveri F, Puppo F. The antiphospholipid syndrome: from pathophysiology to treatment. Clin Exp Med. 2017 Aug;17(3):257-267. doi: 10.1007/s10238-016-0430-5.

Vlachoyiannopoulos PG, Routsias JG. A novel mechanism of thrombosis in antiphospholipid antibody syndrome. J Autoimmun. 2010 Nov;35(3):248-55. doi: 10.1016/j.jaut.2010.06.015.

Seshan SV, Franzke CW, Redecha P, Monestier M, Mackman N, Girardi G. Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies. Blood. 2009 Aug 20;114(8):1675-83. doi: 10.1182/blood-2009-01-199117.

Lonze BE, Singer AL, Montgomery RA. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med. 2010 May 6;362(18):1744-5. doi: 10.1056/NEJMc0910965.

Shapira I, Andrade D, Allen SL, Salmon JE. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum. 2012 Aug;64(8):2719-23. doi: 10.1002/art.34440.

Hadaya K, Ferrari-Lacraz S, Fumeaux D, et al. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant. 2011 Nov;11(11):2523-7. doi: 10.1111/j.1600-6143.2011.03696.x.

Canaud G, Kamar N, Anglicheau D, et al. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant. 2013 Aug;13(8):2179-85. doi: 10.1111/ajt.12319.

Canaud G, Bienaime F, Tabarin F, et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med. 2014 Jul 24;371(4):303-12. doi: 10.1056/NEJMoa1312890.

Al-Homood IA. Thrombosis in systemic lupus erythematosus: a review article. ISRN Rheumatol. 2012;2012:428269. doi: 10.5402/2012/428269.

Boltin D, Boguslavski V, Sagi L, Goor Y, Elkayam O. Antiphospholipid syndrome presenting as unilateral renal artery occlusion: case report and literature review. Rheumatol Int. 2009 May;29(7):831-5. doi: 10.1007/s00296-008-0779-1.

Tektonidou MG. Antiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment. Front Immunol. 2018 May 31;9:1181. doi: 10.3389/fimmu.2018.01181.

Peleg H, Bursztyn M, Hiller N, Hershcovici T. Renal artery stenosis with significant proteinuria may be reversed after nephrectomy or revascularization in patients with the antiphospholipid antibody syndrome: a case series and review of the literature. Rheumatol Int. 2012 Jan;32(1):85-90. doi: 10.1007/s00296-010-1559-2.

Vellanki VS, Parvathina S, Gondi S, Yadla M, Chenu KK, Vishnubhotla S. Post-partum bilateral renal cortical necrosis in antiphospholipid syndrome and systemic lupus erythematosus. Saudi J Kidney Dis Transpl. 2013 May;24(3):549-52.

Cervera R, Rodríguez-Pintó I, G Espinosa on behalf of the Task Force on Catastrophic Antiphospholipid Syndrome. Catastrophic antiphospholipid syndrome: task force report summary. Lupus. 2014 Oct;23(12):1283-5. doi: 10.1177/0961203314540764.

Rodriguez-Pinto I, Espinosa G, Cervera R. Catastrophic APS in the context of other thrombotic microangiopathies. Curr Rheumatol Rep. 2015 Jan;17(1):482. doi: 10.1007/s11926-014-0482-z.

Gerhardsson J, Sundelin B, Zickert A, Padyukov L, Svenungsson E, Gunnarsson I. Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-up. Arthritis Res Ther. 2015 Apr 27;17:109. doi: 10.1186/s13075-015-0614-5.

Majdan М. Kidney involvement in antiphospholipid syndrome – current diagnostic and management problems. Reumatologia. 2017;55(5):213-214. doi: 10.5114/reum.2017.71626.

Bommer M, Wölfle-Guter M, Bohl S, Kuchenbauer F. The Differential Diagnosis and Treatment of Thrombotic Microangiopathies. Dtsch Arztebl Int. 2018 May 11;115(19):327-334. doi: 10.3238/arztebl.2018.0327.

Sciascia S, Baldovino S, Schreiber K, Solfietti L, Roccatello D. Antiphospholipid syndrome and the Kidney. Semin Nephrol. 2015 Sep;35(5):478-86. doi: 10.1016/j.semnephrol.2015.08.009.

Cervera R, Tektonidou MG, Espinosa G, et al. Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. Lupus. 2011 Feb;20(2):165-73. doi: 10.1177/0961203310395051.

de Azevedo FVA, Maia DG, de Carvalho JF, Rodrigues CEM. Renal involvement in antiphospholipid syndrome. Rheumatol Int. 2018 Oct;38(10):1777-1789. doi: 10.1007/s00296-018-4040-2.

Pons-Estel GJ, Andreoli L, Scanzi F, Cervera R, Tincani A. The antiphospholipid syndrome in patients with systemic lupus erythematosus. J Autoimmun. 2017 Jan;76:10-20. doi: 10.1016/j.jaut.2016.10.004.

Ünlu O, Zuily S, Erkan D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol. 2016 Jun;3(2):75-84. doi: 10.5152/eurjrheum.2015.0085.

Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev. 2010 Dec;10(2):74-9. doi: 10.1016/j.autrev.2010.08.005.

Bienaime F, Legendre C, Terzi F, Canaud G. Antiphospholipid syndrome and kidney disease. Kidney Int. 2017 Jan;91(1):34-44. doi: 10.1016/j.kint.2016.06.026.

American College of Obstetricians and Gynecologists, Task force on hypertension in pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013 Nov;122(5):1122-31. doi: 10.1097/01.AOG.0000437382.03963.88.

de Groot PG, Urbanus RT. The significance of autoantibodies against β2-glycoprotein. Blood. 2012 Jul 12;120(2):266-74. doi: 10.1182/blood-2012-03-378646.

Miranda JM, Jara LJ, Calleja C, Saavedra MA, Bustamante RM, Angeles U. Clinical significance of antiphospholipid syndrome nephropathy (APSN) in patients with systemic lupus erythematosus (SLE). Reumatol Clin. 2009 Sep-Oct;5(5):209-13. doi: 10.1016/j.reuma.2008.12.011.

Puente D, Pombo G, Forastiero R. Current management of antiphospholipid syndrome-related thrombosis. Expert Rev Cardiovasc Ther. 2009 Dec;7(12):1551-8. doi: 10.1586/erc.09.112.

Del Papa N, Vaso N. Management of Antiphospholipid Syndrome. Ther Adv Musculoskelet Dis. 2010 Aug;2(4):221-7. doi: 10.1177/1759720X10365969.

Cervera R, Rodríguez-Pintó I, Colafrancesco S, et al. 14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. Autoimmun Rev. 2014 Jul;13(7):699-707. doi: 10.1016/j.autrev.2014.03.002.

Rodriguez-Pintó I, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: The current management approach. Best Pract Res Clin Rheumatol. 2016 Apr;30(2):239-249. doi: 10.1016/j.berh.2016.07.004.

Erkan D, Aguiar CL, Andrade D, et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014 Jun;13(6):685-96. doi: 10.1016/j.autrev.2014.01.053.

Hadaya K, Ferrari-Lacraz S, Fumeaux D, et al. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant. 2011 Nov;11(11):2523-7. doi: 10.1111/j.1600-6143.2011.03696.x.

Jayne DRW, Bruchfeld NA, Harper L, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017 Sep;28(9):2756-2767. doi: 10.1681/ASN.2016111179.

Pons I, Espinosa G, Cervera R. Efficacy and safety of rituximab in the treatment of primary antiphospholipid syndrome: analysis of 24 cases from the bibliography review. Med Clin (Barc). 2015 Feb 2;144(3):97-104. doi: 10.1016/j.medcli.2014.01.034.

Erkan D, Vega J, Ramon G, Kozora E, Lockshin MD. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum. 2013 Feb;65(2):464-71. doi: 10.1002/art.37759.

Win K, Rodgers GM. New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am J Hematol. 2014 Oct;89(10):1017. doi: 10.1002/ajh.23797.

Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019 May 15. pii: annrheumdis-2019-215213. doi: 10.1136/annrheumdis-2019-215213.

Copyright (c) 2019 KIDNEYS

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© "Publishing House "Zaslavsky", 1997-2019


   Seo анализ сайта